ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

icotrokinra

Also written as “JNJ-77242113”, “Icotrokinra” and “PN-235”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease, led by 2 companies.

Drug pageIcotrokinra: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 18, 202314 company-led studies, 7 open or runningLicense: Protagonist Therapeutics → Johnson & Johnson, 2017Next primary completion: Feb 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson137 open or runningphase 3since Oct 18, 2023Sep 21, 2021Feb 10, 2027phase 3 · NCT06807424
Protagonist Therapeuticsits history only10 open or runningphase 1since Oct 29, 2020Oct 29, 2020none ahead

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. 2017Johnson & Johnson licensed it from Protagonist TherapeuticsLicenseWorldwide rights from phase 2 on · agreed · Johnson & Johnson
  2. Sep 21, 2021First study: phase 1 study in HealthyFirst studyNCT05062200 · 36 enrolled · Japan
  3. Jan 24, 2022Phase 2 study in Plaque PsoriasisNCT05223868 · 255 enrolled · United States, Canada, France and more
  4. Apr 27, 2022Phase 2 study in Plaque PsoriasisNCT05357755 · 90 enrolled · United States, Canada, France and more
  5. May 3, 2022Phase 2 study in Plaque PsoriasisNCT05364554 · 227 enrolled · United States, Canada, France and more
  6. Jan 20, 2023Phase 1 study in HealthyNCT05703841 · 30 enrolled · China
  7. Sep 15, 2023Phase 2 study in Colitis, UlcerativeNCT06049017 · 252 enrolled · United States, Argentina, Australia and more
  8. Oct 18, 20232 phase 3 studies in Plaque PsoriasisNCT06095115, NCT06095102
  9. Feb 29, 2024Phase 3 study in PsoriasisNCT06295692 · 19 enrolled · Japan
  10. Feb 29, 2024Named icotrokinraINNProposed as its International Nonproprietary Name in WHO's List 130 · before, JNJ-77242113, PN-235
  11. Jan 29, 2025Phase 3 study in Arthritis, PsoriaticNCT06807424 · 813 enrolled · United States, Argentina, Australia and more
  12. Mar 13, 2025Phase 3 study in Arthritis, PsoriaticNCT06878404 · 552 enrolled · United States, Argentina, Australia and more
  13. Sep 22, 20252 phase 3 studiesNCT07196748, NCT07196722

Ahead

  1. Feb 10, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06807424
  2. Jan 14, 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT07196748
  3. Sep 19, 2028Primary completion: phase 3 study in Crohn DiseaseNCT07196722

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07196748Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingJan 14, 2028896
NCT07196722Crohn Disease · United States, Argentina, Australia and more3RecruitingSep 19, 20281,092
NCT06878404Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingMay 25, 2026552
NCT06807424Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingFeb 10, 2027813
NCT06295692Psoriasis · Japan3Active, not recruitingJan 14, 202519
NCT06095115Plaque Psoriasis · United States, Argentina, Australia and more3Active, not recruitingJul 29, 2024684
NCT06095102Plaque Psoriasis · United States, Argentina, Canada and more3Active, not recruitingJun 19, 2024311
NCT06049017Colitis, Ulcerative · United States, Argentina, Australia and more2CompletedSep 26, 2024252
NCT05703841Healthy · China1CompletedApr 7, 202330
NCT05364554Plaque Psoriasis · United States, Canada, France and more2CompletedSep 29, 2023227
NCT05357755Plaque Psoriasis · United States, Canada, France and more2CompletedMar 23, 202390
NCT05223868Plaque Psoriasis · United States, Canada, France and more2CompletedDec 15, 2022255
NCT05062200Healthy · Japan1CompletedSep 28, 202236

How it is read

Names in the registry

  • “JNJ-77242113”, 9 entries
  • “Icotrokinra”, 4 entries
  • “PN-235”, 1 entry

Codes read as this program: PN235.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.